The HORIZONS study aims to find out more about how cancer and its treatment affect a person’s health and wellbeing. This could help provide better care and support for people living with and beyond cancer in the future.
The study hoped to recruit 3,000 people with a new diagnosis of diffuse large B-cell lymphoma (DLBCL), breast cancer, cervical cancer, endometrial cancer, ovarian cancer or vulval cancer and the good news is this target was reached! Between September 2016 and March 2019, 3,334 people from across the UK agreed to take part in the study. In total, 719 of these had DLBCL.
- People with DLBCL who entered the Horizons study were an average age of 66 when they were diagnosed. The youngest person with DLBCL was 23 and the oldest was 94.
- Around 4 in 10 had early-stage (stage 1 or 2) DLBCL and 1 in 3 had B symptoms (fever, night sweats and unexplained weight loss) when they were diagnosed.
- Almost 2 in 3 people with DLBCL also had other medical conditions.
- Most of the people with DLBCL who entered the Horizons study were white British and just over half were men.
- Almost 3 in 4 were married or living with their partner. Around 2 in 10 had full-time jobs.
The people who entered the study completed questionnaires about their health and wellbeing before they started their cancer treatment. They will be followed up for 5 years, with repeat questionnaires at various points during and after treatment. Information from their medical records will also be collected. We will continue to report on updates and learning as it is shared.
Visit Lymphoma TrialsLink for more information on the latest lymphoma research and clinical trials, including the HORIZONS study.
29 November 2019